ACS sub-journal: Chinese and French scientists have teamed up to find that regulating copper ion levels in the brain is expected to reduce memory loss in Alzheimer's disease

18, 2020 /--- -- Alzheimer's disease (AD) is characterized by amyloid plaques in the patient's brain.
amyloid plaques are coagulants formed outside cells by protein fragments and are found in a variety of neurodegenerative diseases.
they capture copper, which is about five times that of a healthy brain.
a new study, researchers from Shenzhen University in China, Guangdong University of Technology and france's National Center for Scientific Research's positional chemistry laboratory have developed a molecule called TDMQ20 that regulates the copper cycle in the brain.
this molecule is a specific copper chelating agent.
results were published online December 16, 2020 in the journal ACS Chemical Neuroscience under the title "TDMQ20, a Specific Copper Chelator, Reduces Memory Wells in Alzheimer's Disease Model Mouses."
from ACS Chemical Neuroscience, 2020, doi:10.1021/acschemneuro.0c00621.
this molecule has been patented: Chinese patent number ZL201610369550.X (application date may 27, 2016, authorization date is July 24, 2018), U.S. patent number US10807957 B2 (application date is November 24, 2018, authorization date is October 20, 2020), PCT application number PCT/CN2017/085886 (application date is November 30, 2017).
this molecule is able to extract copper trapped in amyloid plaques and reintroduct it into the brain's normal enzyme pathways, which require copper to function.
the researchers built three models of mice with Alzheimer's disease: one for genetically modified mice and two for new models of non-GMO mice.
these non-GMO mouse models are closest to the reality of Alzheimer's disease.
the three Alzheimer's mice was given oral this molecule to suppress memory loss in sick mice.
the findings opens up a new avenue of treatment that may prove effective in the early stages of Alzheimer's disease in humans.
researchers are now seeking pharmaceutical partners to conduct preclinical trials of the drug candidate.
( Bioon.com)1.Jie Zhao et al. TDMQ20, a Specific Copper Chelator, Reduces Memory Impairments in Alzheimer's Disease Mouse Models. ACS Chemical Neuroscience, 2020, doi:10.1021/acschemneuro.0c00621.2.Alzheimer's disease: regulating copper in the brain stops memory loss among mice。